1. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B
- Author
-
Kim, W. Ray, Loomba, Rohit, Berg, Thomas, Schall, Raul E. Aguilar, Yee, Leland J., Dinh, Phillip V., Flaherty, John F., Martins, Eduardo B., Therneau, Terry M., Jacobson, Ira, Fung, Scott, Buti, Maria, Marcellin, Patrick, Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Gastroenteroloji Bilim Dalı., and Gürel, Selim
- Subjects
Male ,History ,Hepatocellular carcinoma ,Antiviral therapy ,Hepatitis B E Antigen ,Entecavir ,Liver Cell Carcinoma ,Chronic hepatitis B ,Predictive score ,Cancer risk ,Liver neoplasms ,Disease ,Adefovir dipivoxil ,Long term care ,Middle aged ,REACH-B ,Risk assessment ,Priority journal ,Fumarate ,Incidence ,Double blind procedure ,Liver biopsy ,Register ,Liver cell carcinoma ,Risk-factors ,Tenofovir disoproxil ,Cirrhosis ,Oncology ,Randomized controlled trial ,Female ,Alanine aminotransferase blood level ,Human ,Adult ,Double-blind method ,Virus infection ,Major clinical study ,Hepatitis B(e) antigen ,Article ,Risk Estimation for hepatocellular carcinoma in chronic hepatitis B ,Age ,Virology ,Virus DNA ,Humans ,Human tissue ,Tenofovir ,Antivirus agent ,Aged ,Drug administration ,Carcinoma, hepatocellular ,Drug administration schedule ,Gender ,Hepatitis B, chronic ,Follow up ,Nonhuman ,digestive system diseases ,Antiviral agents ,Liver cirrhosis ,Alanine aminotransferase ,Prediction ,Standardized incidence ratio ,Controlled study ,Complication ,Cancer incidence ,Analogs - Abstract
BACKGROUND: Efficacy trials have shown that antiviral therapy improves the outcomes of patients with chronic hepatitis B virus (HBV) infection. However, prospective data regarding the effect of antiviral therapy on the incidence of hepatocellular carcinoma (HCC), especially among patients without cirrhosis, are limited. The authors examined the impact of tenofovir disoproxil fumarate (TDF) on the incidence of HCC using a validated prediction model. METHODS: The incidence of HCC in patients treated with TDF was obtained in the pivotal TDF registration studies after 384 weeks of follow-up. The predicted risk of HCC in individual patients was calculated using the Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) model, which estimates HCC incidence for up to 10 years based on age, sex, alanine aminotransferase level, hepatitis B e antigen status, and HBV-DNA. Standardized incidence ratios (SIRs) were calculated comparing the observed and predicted numbers of HCC cases in the study cohort. RESULTS: Among 634 patients with evaluable baseline biopsies, 152 had cirrhosis (Ishak fibrosis score of 5 or 6) and 482 did not. During the 384 weeks of study, 14 cases of HCC were reported, with 4 occurring within the first year. The incidence of HCC was 0.37% per year in the study as a whole (0.28% among patients without cirrhosis and 0.65% among patients with cirrhosis). Among patients without cirrhosis, the observed incidence of HCC was significantly lower than predicted (SIR, 0.40; 95% confidence interval, 0.199-0.795). The last HCC case in a patient with cirrhosis occurred around week 192 with an SIR of 0.51 (95% confidence interval, 0.231-1.144) reported at week 384. CONCLUSIONS: Based on the REACH-B risk calculator, long-term therapy with TDF was associated with a reduced incidence of HCC among patients without cirrhosis who met treatment criteria. American Gastroenterological Association Foundation-Sucampo-ASP Designated Research Award in Geriatric Gastroenterology T. Franklin Williams Scholarship Award Atlantic Philanthropies Inc John A. Hartford Foundation Association of Specialty Professors American Gastroenterological Association Gilead Sciences United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) (K23DK090303)
- Published
- 2015